Latest News
Original English headlines · Newest first · U.S. Eastern Time
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update#JSPRBig-ticket holiday items may be harder to find as shipping costs riseAileron Therapeutics reports Q3 resultsOut of 503 stocks in the S&P 500, $NVDA was the second worst performer last week, at lower by nearly 13%.#NVDAThis has to be my first tweet ever with both Vince McMahon and Papa John in it.Wild chart from @DualityResearch today that shows South Korean exports aren't slowing down at all. 😲😳Rolling correlations: 10y yield and oil vs. S&P 500Profitable small caps still trouncing non-profitable ones YTDBREAKING: Nasdaq 100 futures erase gains and fall over -1% on the day as chip stocks sell off sharply.BREAKING: Nasdaq 100 futures extend losses to -1.7% in premarket trading as Nvidia, $NVDA, falls more than -5%.#NVDACan Workers Predict Job Finding and Job Loss?Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update#LRMRMapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update#MPLTNervGen Reports Third Quarter 2026 Financial Results and Provides Business UpdatesBeyond Oil Reports Third Quarter 2026 Financial Results and Provides Business UpdateFortitude Reports Financial and Operating Results for the Nine Months Ended September 30, 2026Edible Garden Reports Third Quarter 2026 Results; Gross Profit Increases 181.7% as Gross Margin More Than Doubles to 23.9%FitLife Brands Announces Third Quarter 2026 Results#FTLFCreative Realities Reports Fiscal 2026 Third Quarter Results#CREXPMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up 785% Year-over-Year to $2.53 Million and Up 94% From Previous Quarter; Files Form 10-Q for Q3 2026; Total Assets of $133.1 Million Include $100.4 Million Held in Trust by Sponsored SPAC#ELABRein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results#RNTXUnicycive Therapeutics GAAP EPS of -$0.25 beats by $0.10#UNCYPrelude Therapeutics reports Q3 results#PRLDPOET Technologies Reports Record Q3 2026 Revenue of $1.03M, Up 244%#POETRubicon Organics Reports Q3 2026 Financial Results#ROMJFAirJoule Technologies Reports Third Quarter 2026 Results and Provides Preliminary 2027 BitSink Outlook#AIRJLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results#LXEOInstil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update#TILInvivyd Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPrelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update#PRLDHyperscale Data lifts preliminary Q3 revenue estimate#GPUSWelcome to 'Grandthropic', the day the gaming and AI industries get tested80% of employees feel more productive from AI. Only 37% of companies see it in profitThe ‘war room’ fighting to reinstate Jensen Huang at Nvidia will have to overcome congressional probes and opposition from the treasury secretary#NVDACreative Media & Community Trust FFO of -$1.30 misses by $0.28, revenue of $27.4M beats by $6.2M#CMCTThe Changing Face of U.S. Corporate R&D Investment← PreviousNext →